Following the White House’s recent proposal for a National Hepatitis C Elimination Plan as part of its Fiscal Year 2024 budget request to Congress, and the fact that key populations for HIV are also at high risk of HCV, Treatment Action Group is organizing a webinar that will highlight best practices and challenges for HCV elimination with a specific focus on high-burden populations.
Treatment Action Group welcomes the inclusion of Ravidasvir on the World Health Organization (WHO) Essential Medicines List (EML) as a direct-acting antiviral (DAA) for the treatment of chronic hepatitis C virus (HCV) infection in adults.
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
As we close another year of unprecedented challenges and achievements, I'm honored to share with you Treatment Action Group's (TAG) 2022 Annual Report.
Treatment Action Group (TAG) is pleased to announce the election of Moe Ari Brown to our Board of Directors.
This policy brief explores barriers such as the high-burden among marginalized communities, the complicated diagnostic process, and the difficulties of finding the missing millions of people with HCV in most high-burden countries.
Save the date for Monday, October 19! TAG’s 2023 Research in Action Awards will honor some of the best and brightest activists, scientists, and leaders in the fight to end HIV, tuberculosis, and hepatitis C across the U.S. and around the world.
TAG is presenting the exhibition “35 Years of Art to End AIDS” at Melissa Morgan Fine Art in Palm Desert, California, from March 17 through April 7, 2023. This exhibit features selected works form our Limited Art Editions collection.
Treatment Action Group (TAG) is pleased to present the exhibition “35 Years of Art to End AIDS” at Melissa Morgan Fine Art in Palm Desert, CA. The exhibition features selected works from TAG’s Limited Art Editions Collection and will run from March 17 through April 7.
The growing pipeline for long-acting therapies and their potential to accelerate various national and global disease elimination goals warrants global community mobilization to ensure equitable access to these therapies.